Wave Life Sciences: director Heidi L Wagner received 74,700 shares

What happened

• Heidi L Wagner, a director of Wave Life Sciences, was granted 10,700 restricted stock units and a derivative option to acquire 64,000 shares on Oct 5, 2026. Both transactions are reported as acquisitions at $0.

Key details

• Transaction date and price: Oct 5, 2026; acquisitions reported at $0 per share.
• Transaction types: 10,700 restricted stock units (RSU) granted (code A); option grant for 64,000 shares reported as a derivative acquisition (code A, derivative).
• Vesting: The RSU and the option each vest 100% on the earlier of the company’s 2027 annual meeting of stockholders or Oct 5, 2027 (footnotes F1 and F2).
• Shares owned after the transaction: not reported in the filing.
• Form 4 filed with the SEC on Oct 7, 2026.

Why it may matter

• These entries are grant awards, not sales or exercises; the option granted was not exercised and no market sale occurred.
• The RSU is a non-market award that vests in the future per the footnote schedule.
• The filing does not show why the insider traded or why the company acted.